Boehringer Ingelheim Vetmedica, Inc.
3902 Gene Field Road
St. Joseph, Missouri 64506
- Phone 866-638-2226
- Fax 816-326-9167
View the video tutorial to learn how to properly administer TODAY in your dairy.
COMING SOON - Dairy producers share how using TODAY helps their herd.
New studies from leading mastitis researchers have confirmed what we’ve known all along: Two treatments are as effective as five when treating mastitis.
Check out this video that explains how a one-day treatment compares to extended therapy.
From efficacy to the economic benefits and value of using fewer antibiotics, these pages will show you how and why TODAY tubes are what you need to manage mastitis on your dairy.
TODAY treats gram-positive and gram-negative bacteria in lactating dairy cows. Using a convenient, single-day treatment, TODAY saves producers time and money when solving problems related to mastitis.
ToDAY should be administered with caution to subjects which have demonstrated some form of allergy, particularly to penicillin. Such reactions are rare; however, should they occur, consult your veterinarian.
Intramammary mastitis treatments of Gram-positive infections is widely reported as beneficial5, so those infections should be the focus of treatment.2
A recent study showed similar efficacy between TODAY and Spectramast LC.TODAY was not inferior to Spectramast LC for clinical or bacteriological cures.3
Two tubes of TODAY given according to the label will result in 60 fewer hours of milk withhold time as compared to using five tubes of Spectramast LC, and reduce time cows spend in the hospital pen by 35 percent. UsingTODAY can also save a 1,000 cow dairy over $13,000 annually.4
In a recent head-to-head study comparing cephapirin and ceftiofur (the active ingredient in Spectramast LC), the authors concluded, “Herds that do not utilize a culture-based approach for the treatment of clinical mastitis may have an economic benefit from selecting cephapirin with the shorter non-saleable milk duration as the first treatment of choice. This would be particularly true in herds that have an average or below-average incidence of Gram-negative organisms causing clinical mastitis.”3
1 Boddie RL, Nickerson SC and Sutherland SF. New design of mastitis tubes reduces infection. Hoard’s Dairyman 1989;134(13):579.
2 Keefe G, ManDonald K, Cameron M. On-Farm culture use experience and impact on antimicrobial use. University of Prince Edward Island, Charolottetown, PE, Canada.
3 Schukken YH, Zurakowski MJ, Rauch BJ, et al. Non-inferiority trial comparing a first-generation cephalosporin with athird-generation cephalosporin in the treatment of non-severe clinical mastitis in dairy cows.
4 Miltenburg JD, de Lange D, Crauwels AP, et al. Incidence of clinical mastitis in a random sample of dairy herds in the southernNetherlands. Vet Rec 1996;139(9):204–207.
5 Hess JL, Neuder LM, Sears PM. Rethinking clinical mastitis therapy. Presented at the 42nd Annual Meeting of the National Mastitis Council; Jan. 27, 2003; Fort Worth, TX.
A Non-Inferiority Trial Comparing a First Generation Cephalosporin with a Third-Generation Cephalosporin in the Treatment of Non-Severe Clinical Mastitis in Dairy Cows.
Minimum Inhibitory Concentrations (MIC) for cephalosporin compounds on their active metabolites for selected mastitis pathogens.
Randomized Non-Inferiority Clinical Trial Evaluating Three Commercial Dry Cow Mastitis Preparations.